Company Overview and News

 
4 Mutual Funds to Ride on Robust Economic Growth

2018-04-12 zacks
The U.S. equity market is lately growing by leaps and bounds. This stupendous run has primarily been fueled by President Trump’s business-friendly approach, a strong domestic economy, reduced tax rates, robust manufacturing activity and improvements in the labor market.
Upvote Downvote

2
Healthcare In Transition

2018-02-19 seekingalpha
With policy changes, integration, and the introduction of technology, healthcare is transforming and stands at a very pivotal point in America.
Upvote Downvote

 
Hiring Rise; Wage Growth Most Since 2009: 5 Top Fund Picks

2018-02-06 zacks
The U.S. economy experienced strong jobs growth in the first month of this year, with average hourly wages posting its best yearly increase since June 2009. Also, the unemployment rate remained at its lowest levels since 2000, reflecting tighter labor market conditions. An upbeat jobs report indicated a rosier economy. Construction, restaurant, healthcare and manufacturing companies led the way for job creation.
Upvote Downvote

 
Trump Completes First Year in Office: 5 Winning Funds

2018-01-26 zacks
All the major bourses moved north and scaled record highs following Donald Trump’s completion of first year in office as the President. During this phase, Trump made a series of diplomatic decisions and several announcements keeping with his protectionist agenda. Specially, his pro-business policies improved investors’ sentiment and gave a boost to sectors like healthcare and technology. Thus, investing in mutual funds having significant exposure to these sectors seems judicious.
Upvote Downvote

1
5 Healthcare Mutual Funds to Buy in 2018

2018-01-03 zacks
Last year was quite an eventful one for the U.S. healthcare sector in particular. The economy witnessed the Republican tax reform becoming law and three rate hikes by the Fed. Thanks to both, healthcare was one of the top performers of 2017. The Health Care Select Sector SPDR ETF (XLV) rallied 19.5% year. This momentum is slated continue in 2018.
Upvote Downvote

 
Unemployment Rate Remains At 17-Year Low: 5 Fund Picks

2017-12-12 zacks
Following a strong show in November with an increase in job additions and a low jobless rate, the sentiment remains positive over U.S. job data. Job additions remained high last month, recovering from workplace disturbances induced by hurricanes Harvey and Irma, which hit several states including Texas and Florida.
Upvote Downvote

 
5 Best-Performing Healthcare Mutual Funds in Q3

2017-11-08 zacks
Broadly encouraging markets and continued investment initiatives have paved the way for the healthcare sector to become one of the top performers this year. The Health Care Select Sector SPDR ETF (XLV) surged 3.1% in 3Q17. Additionally, President Trump has failed repeatedly to repeal the Affordable Care Act (ACA), also known as Obamacare. This has protected gains for several sections of the sector.
Upvote Downvote

 
Where To Invest Now

2017-09-23 seekingalpha
While I remain cautious on the market as a whole, I continue to be invested in a select group of equities across the globe.
Upvote Downvote

 
5 Best-Rated T. Rowe Price Mutual Funds For High Returns

2016-09-18 seekingalpha
T. Rowe Price is a renowned publicly owned investment management firm, headquartered in Baltimore, Maryland. The company was founded in 1937 by Thomas Rowe Price, Jr. The company manages assets worth $725.5 billion (as of September 30, 2015). It prides itself in having more than 5,000 employees across the world. The company offers a full range of investment planning and guidance tools. It also offers mutual funds, subadvisory services, retirement plans and separate account management for individual clients.
Upvote Downvote

1
Best Performing Mutual Funds Over The Last 1, 3 And 5 Years

2016-09-18 seekingalpha
Market trends so far this year has not been as robust as the previous two years. Like 2014, markets had started with a dismal January but a robust February followed close on the heels. However this time benchmarks have failed to sustain strong gains. In fact, the recent market rout is in stark contrast to the multiple highs that benchmarks kept scoring in recent years. Among other factors, China's economic concerns and global growth worries, Greece debt negotiation, a stronger dollar and dismal earnings season for both the first and second quarter have taken the sheen away.
Upvote Downvote

1
Top Mutual Funds With Best Returns In 10 Years

2016-09-18 seekingalpha
Ten years are certainly a lot of time for funds to prove their mettle. Occasional hiccups or economic events may deter a fund's performance. But over the long term a fund should ideally be able to post positive returns. If that is not the case, then we are compelled to question how those underperformers are still around. In a previous article we identified the funds with worst performances in 10 years.
Upvote Downvote

 
4 Top-Ranked Healthcare Mutual Funds To Boost Your Return

2016-09-17 seekingalpha
When markets are plying through choppy waters, investors often rely on the healthcare sector to safeguard their investments. This is because the demand for healthcare services does not vary so much with market conditions, making them a safe haven in difficult times. Many pharma companies also generate regular dividends, which go a long way in softening the blow dealt by plummeting share prices. Mutual funds are the perfect choice for investors looking to enter this sector, since they possess the advantages of wide diversification and analytical insight.
Upvote Downvote

 
4 Healthcare Mutual Funds To Buy On Bright Prospects

2016-07-22 seekingalpha
Healthcare is one of the major sectors that showed a remarkable rebound recently after bleeding heavily since the start of the year. Bright prospects of the sector and an overall positive investor sentiment spurred demand for its securities. So, the addition of favorably ranked healthcare mutual funds may lead to healthy returns.
Upvote Downvote

 
4 Healthcare Mutual Funds to Buy on Bright Prospects

2016-07-21 zacks
Healthcare is one of the major sectors that showed a remarkable rebound recently after bleeding heavily since the start of the year. Bright prospects of the sector and an overall positive investor sentiment spurred demand for its securities. So, the addition of favorably ranked healthcare mutual funds may lead to healthy returns.
Upvote Downvote

 
Is T. Rowe Price Health Sciences Fund (PRHSX) Worth Another Look?

2016-05-16 zacks
T. Rowe Price Health Sciences (PRHSX - MF report) a Zacks Ranked #2 (Buy) was incepted in December 1995 and is managed by T.Rowe Price Associates. PRHSX’s main objective is long-term capital appreciation. PRHSX invests at least 80% of its net assets in common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...